Nextgen Biomed Ltd, through its subsidiary, Dermipsor Ltd., develops medicines for the treatment of external skin diseases. It is involved in the development of DPS-101, a topical ointment that is in Phase II/III trials for the treatment of psoriasis. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.
nextgen biomed ltd (NXGN:Tel Aviv)
132 Menachem Begin
Tel Aviv, 67021
Phone: 972 3 607 0320
Fax: 972 9 951 8666--
|No competitor information is available for NXGN.|
|View Industry Companies|
|Price/Cash Flow||--||Not Meaningful|
Sponsored Financial Commentaries
To contact NEXTGEN BIOMED LTD, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.